Tag: 29

The Venice, California surf and swimwear label, founded by designer Nicola Morgan, brought UPF50+ sun protection in Italian ECONYL® regenerated nylon and Japanese limestone neoprene to the runway at RISE by Paraiso Miami Swim Week, presenting its Spring/Summer 2026 collection and a first look at Fall 2026.

Communiqué de presse
Paris, le 18 juin 2026

Press release
Paris, 18 June 2026

Malibu, California, June 18, 2026 (GLOBE NEWSWIRE) -- Trio Petroleum Corp ("Trio" or the "Company") (NYSE American: TPET) is pleased to provide shareholders with an update regarding its acquisition strategy and ongoing efforts to build a diversified portfolio of cash-flowing oil and gas assets.

Bank of Åland Plc
Stock Exchange Release
June 18, 2026, 9.00 EEST

SINGAPORE, June 17, 2026 (GLOBE NEWSWIRE) -- China's largest international entrepreneurship platform is setting its sights on Singapore, positioning the city-state as its gateway to Southeast Asia. HICOOL 2026 Global Startup Competition wrapped up its Singapore leg on June 4-5 at NUS, drawing nearly 40 teams from China, Singapore, Indonesia, Thailand, Japan, South Korea, India, France, Switzerland, Germany, and beyond. HICOOL has run its Singapore leg for two consecutive years, enabling Singapore's innovation ecosystem and China's industrial landscape to empower each other — creating a genuine two-way flow of technology and markets.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~